HDAC6 and breast cancer: Combination inhibition of HSP90‐HDAC6 interplay has been considered as an attractive strategy and achieved preclinical progress in human leukemia and breast cancer.20, 21 HDAC6 and HSP90 regulate each other reciprocally in many aspects.